NIH Highlighted Topic: Advancing Microbiome Science Through Multidisciplinary Mechanistic Investigations of the Human Microbiome in Health and Disease
Below is a brief summary. Please check the full solicitation before applying (link in resources section).
Executive Summary:
The National Institutes of Health (NIH) is seeking innovative research proposals through the SBIR Program focused on advancing mechanistic investigations of the human microbiome and its influence on human health and disease. NIH is particularly interested in technologies and therapeutic approaches that improve understanding of host-microbiome interactions and translate microbiome science into novel diagnostics, therapeutics, disease prevention strategies, and personalized medicine solutions.
The human microbiome plays a critical role in immune function, metabolism, neurological health, inflammation, cancer progression, and chronic disease outcomes. While many studies have identified associations between microbiome composition and disease, significant gaps remain in understanding the mechanistic pathways driving these interactions. NIH is encouraging multidisciplinary projects that move beyond correlation-based studies to investigate molecular mechanisms, microbial metabolites, host signaling pathways, and therapeutic interventions capable of modulating microbiome function.
Companies developing microbiome therapeutics, probiotics, prebiotics, AI-enabled microbiome analytics platforms, computational biology tools, biomarker technologies, organ-on-chip systems, multi-omic platforms, microbial engineering technologies, or precision medicine applications may be strong candidates for funding. NIH is especially interested in projects focused on infectious disease, autoimmune disorders, cancer, metabolic disease, neuropsychiatric conditions, aging, oral health, women’s health, and immune-mediated diseases.
Through the NIH SBIR Program, U.S. small businesses may apply for up to $323,090 in Phase I funding and up to $2,153,927 in Phase II funding to support research, development, validation, and commercialization activities. Applications are accepted on January 5th, April 5th, and September 5th annually, with funding typically beginning approximately 9 months after submission.
This highlighted topic is supported primarily by the National Institute of Allergy and Infectious Diseases (NIAID), the National Center for Complementary and Integrative Health (NCCIH), the National Eye Institute (NEI), the National Institute on Aging (NIA), the National Institute of Dental and Craniofacial Research (NIDCR), the National Cancer Institute (NCI), and the Office of Research on Women’s Health (ORWH), all of which may give special consideration to high-impact applications advancing microbiome science, translational therapeutics, systems biology, and precision health technologies.
How much funding would I receive?
Awards provide up to $323,090 for Phase I projects (up to 2 years) and $2,153,927 for Phase II projects (up to 3 years). Some topics approved by NIH may exceed these limits. Fast-Track and Phase IIB (follow-on) options allow continuous or extended funding beyond Phase II.
What could I use the funding for?
Funding may support the research, development, validation, and commercialization of technologies and therapeutic approaches focused on microbiome science, host-microbe interactions, and microbiome-based disease prevention and treatment.
Eligible activities may include:
Development of microbiome-targeted therapeutics, probiotics, prebiotics, or microbial metabolite interventions
AI and machine learning platforms analyzing microbiome composition, host interactions, and disease risk
Multi-omic technologies integrating microbiome, genomic, metabolomic, epigenetic, and clinical data
Organ-on-chip, tumor-on-chip, and advanced in vitro systems for microbiome research
Biomarker discovery technologies for microbiome-associated diseases and treatment response
Computational biology platforms modeling host-microbe interactions and microbial signaling pathways
Research into microbiome impacts on infectious disease, autoimmune disease, cancer, metabolic disorders, neurological conditions, and aging
Development of microbiome engineering and targeted pathogen elimination technologies
Oral microbiome therapeutics for dental disease, periodontal disease, and oral cancers
Studies evaluating microbiome effects on immune checkpoint inhibitors and cancer therapy response
Nutritional, dietary, natural product, and complementary intervention research related to microbiome modulation
Precision medicine approaches incorporating microbiome and microbial metabolite profiling
Longitudinal microbiome monitoring systems and predictive analytics tools
Translational research evaluating microbiome-driven treatment response and prevention strategies
Validation studies, prototype development, translational research, and regulatory preparation activities
Commercialization planning and scale-up activities for microbiome technologies and therapeutics
Funding may also support personnel, laboratory testing, software development, computational infrastructure, prototype fabrication, sequencing technologies, intellectual property protection, commercialization strategy development, and other research and development activities necessary to advance a commercially viable solution aligned with NIH priorities.
Are there any additional benefits I would receive?
Beyond the formal funding award, awardees gain several strategic advantages:
Government Validation and Credibility:
Being selected for an NIH-backed SBIR grant signals technical excellence and alignment with national health and biomedical priorities. This validation builds investor and partner confidence.Enhanced Visibility and Market Recognition:
Awardees are featured in NIH and HHS announcements, helping attract partnerships, media attention, and future contracting opportunities.Access to the Federal Innovation Ecosystem:
Recipients join a national network of researchers and agencies advancing life science innovation, often opening doors to collaborations with NIH laboratories and federal health programs.Stronger Commercial and Exit Potential:
By maturing technology through nondilutive funding, companies strengthen valuation, de-risk commercialization, and increase attractiveness for acquisition or follow-on private investment.
What is the timeline to apply and when would I receive funding?
Applications are accepted each year on January 5th, April 5th, and September 5th. Funding is received approximately 9 months after submission.
Where does this funding come from?
Funding comes from the U.S. Department of Health and Human Services, with statutory set-asides requiring NIH, CDC, and FDA to devote portions of their extramural R&D budgets (3.2% for SBIR, 0.45% for STTR) to support small business innovation.
Who is eligible to apply?
Applicants must be U.S. small business concerns (SBCs) that:
Are organized for profit with a U.S. place of business.
Have ≤ 500 employees including affiliates.
Are > 50% owned by U.S. citizens or permanent residents, qualifying U.S. entities, or combinations thereof.
What companies and projects are likely to win?
Projects that demonstrate:
A clear unmet medical or public-health need,
Strong scientific rationale and feasibility,
High commercialization potential, supported by a realistic market and regulatory strategy, and
Alignment with an NIH Institute’s or CDC/FDA Center’s specific research mission (e.g., infectious disease, digital health, diagnostics, therapeutics, or data analytics).
Competitive applicants often have an early prototype, preliminary data, and a defined path to market adoption.
Are there any restrictions I should know about?
Companies must complete multiple federal registrations (SAM.gov, Grants.gov, eRA Commons, SBA Company Registry) before applying.
Foreign entities are not eligible.
Disclosure of foreign affiliations and compliance with national security screening are mandatory. Currently we do not recommend any sort of foreign affiliation.
How long will it take me to prepare an application?
For a first-time applicant, preparing a competitive submission will likely take 120–200 hours in total.
How can BW&CO help?
Our team specializes in complex federal R&D proposals and can:
Triple your likelihood of success through proven strategy and insider-aligned proposal development
Reduce your time spent on the proposal by 50–80%, letting your team focus on technology and operations
Ensure you are targeting the best opportunity for your project and positioning your company for long-term growth.
